Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it ...

Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.

BofA lowered the firm’s price target on Biogen (BIIB) to $163 from $178 and keeps a Neutral rating on the shares. The firm calls Biogen “one of ...

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...